These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22453559)

  • 21. UNITAID can address HCV/HIV co-infection.
    von Schoen-Angerer T; Cohn J; Swan T; Piot P
    Lancet; 2013 Feb; 381(9867):628. PubMed ID: 23439101
    [No Abstract]   [Full Text] [Related]  

  • 22. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
    [No Abstract]   [Full Text] [Related]  

  • 23. Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?
    Hoefs JC; Morgan TR
    Hepatology; 2007 Dec; 46(6):1671-4. PubMed ID: 18046713
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
    Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
    Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatitis C virus infection.
    Bacon BR; Di Bisceglie AM
    N Engl J Med; 2001 Nov; 345(19):1425-6; author reply 1427-8. PubMed ID: 11794183
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatitis C: the 'silent stalker'.
    Harkness GA
    Am J Nurs; 2003 Sep; 103(9):24-5. PubMed ID: 14506802
    [No Abstract]   [Full Text] [Related]  

  • 27. Interferon for hepatitis C patients with psychiatric disorders.
    Rifai MA; Bozorg B; Rosenstein DL
    Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
    [No Abstract]   [Full Text] [Related]  

  • 28. [Long-acting interferon: studies on pegylated interferon].
    Ma H; Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):78-9. PubMed ID: 11856520
    [No Abstract]   [Full Text] [Related]  

  • 29. Predictors of response of U.S. veterans to treatment for the hepatitis C virus.
    Riley TR
    Hepatology; 2008 Jan; 47(1):356; author reply 356-7. PubMed ID: 18161713
    [No Abstract]   [Full Text] [Related]  

  • 30. Hepatitis C treatment, HAART and side effects.
    TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865
    [No Abstract]   [Full Text] [Related]  

  • 31. Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C: reappraisal of effectiveness on the basis of trial sequential analysis.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):246-8. PubMed ID: 24366456
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful Hepatitis C Eradication With Preservation of Renal Function in a Liver/kidney Transplant Recipient Using Pegylated Interferon and Ribavirin.
    Mukherjee S; Ariyarantha K
    Transplantation; 2007 Nov; 84(10):1374-5. PubMed ID: 18049127
    [No Abstract]   [Full Text] [Related]  

  • 33. PegIFN/ribavirin during acute HCV coinfection.
    Bernard EJ
    IAPAC Mon; 2004 Jul; 10(7):260-1. PubMed ID: 15624247
    [No Abstract]   [Full Text] [Related]  

  • 34. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
    Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Bruno S; Craxì A; Cammà C;
    Dig Liver Dis; 2014 Oct; 46(10):936-42. PubMed ID: 25066806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HCV infection in the setting of HIV: prevalence, disease, treatment.
    Laurence J
    AIDS Read; 2006 Mar; 16(3):115-6. PubMed ID: 16538952
    [No Abstract]   [Full Text] [Related]  

  • 36. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 37. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
    Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
    Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders.
    Nakamura J; Toyabe SI; Aoyagi Y; Akazawa K
    J Viral Hepat; 2008 Apr; 15(4):293-9. PubMed ID: 18307591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Hepatitis C (HCV) treatment is not a "one size fits all".
    Bukeirat FA; Bukeirat MM
    W V Med J; 2012; 108(2):20, 22-4. PubMed ID: 22655431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of liver iron in hepatitis C antiviral treatment.
    Musallam KM; Sharara AI; Inati A; Taher AT
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):769. PubMed ID: 20440118
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.